Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab

The introduction of a third‐dose vaccination along with new variants of concern raises questions regarding serology and T‐cell responses in patients with multiple sclerosis (pwMS) treated with B‐cell depletion who develop attenuated humoral response to vaccines. The aim of this study was to longitud...

Descripción completa

Detalles Bibliográficos
Autores principales: Brill, Livnat, Raposo, Catarina, Rechtman, Ariel, Zveik, Omri, Levin, Netta, Oiknine‐Djian, Esther, Wolf, Dana G., Vaknin‐Dembinsky, Adi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9082479/
https://www.ncbi.nlm.nih.gov/pubmed/35243687
http://dx.doi.org/10.1002/ana.26343
_version_ 1784703213364051968
author Brill, Livnat
Raposo, Catarina
Rechtman, Ariel
Zveik, Omri
Levin, Netta
Oiknine‐Djian, Esther
Wolf, Dana G.
Vaknin‐Dembinsky, Adi
author_facet Brill, Livnat
Raposo, Catarina
Rechtman, Ariel
Zveik, Omri
Levin, Netta
Oiknine‐Djian, Esther
Wolf, Dana G.
Vaknin‐Dembinsky, Adi
author_sort Brill, Livnat
collection PubMed
description The introduction of a third‐dose vaccination along with new variants of concern raises questions regarding serology and T‐cell responses in patients with multiple sclerosis (pwMS) treated with B‐cell depletion who develop attenuated humoral response to vaccines. The aim of this study was to longitudinally evaluate humoral and cellular response to SARS‐CoV‐2 mRNA vaccine in ocrelizumab‐treated pwMS before and following a third vaccine dose. Following the third vaccine dose, patients who are low or nonresponders following initial vaccination did not increase antibody titers. In healthy controls and ocrelizumab‐treated pwMS, cellular response decreased 6 months after initial vaccination and increased significantly after the third dose. ANN NEUROL 2022;91:796–800
format Online
Article
Text
id pubmed-9082479
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-90824792022-05-09 Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab Brill, Livnat Raposo, Catarina Rechtman, Ariel Zveik, Omri Levin, Netta Oiknine‐Djian, Esther Wolf, Dana G. Vaknin‐Dembinsky, Adi Ann Neurol Brief Communication The introduction of a third‐dose vaccination along with new variants of concern raises questions regarding serology and T‐cell responses in patients with multiple sclerosis (pwMS) treated with B‐cell depletion who develop attenuated humoral response to vaccines. The aim of this study was to longitudinally evaluate humoral and cellular response to SARS‐CoV‐2 mRNA vaccine in ocrelizumab‐treated pwMS before and following a third vaccine dose. Following the third vaccine dose, patients who are low or nonresponders following initial vaccination did not increase antibody titers. In healthy controls and ocrelizumab‐treated pwMS, cellular response decreased 6 months after initial vaccination and increased significantly after the third dose. ANN NEUROL 2022;91:796–800 John Wiley & Sons, Inc. 2022-03-24 2022-06 /pmc/articles/PMC9082479/ /pubmed/35243687 http://dx.doi.org/10.1002/ana.26343 Text en © 2022 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Brief Communication
Brill, Livnat
Raposo, Catarina
Rechtman, Ariel
Zveik, Omri
Levin, Netta
Oiknine‐Djian, Esther
Wolf, Dana G.
Vaknin‐Dembinsky, Adi
Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab
title Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab
title_full Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab
title_fullStr Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab
title_full_unstemmed Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab
title_short Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab
title_sort severe acute respiratory syndrome coronavirus 2 third vaccine immune response in multiple sclerosis patients treated with ocrelizumab
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9082479/
https://www.ncbi.nlm.nih.gov/pubmed/35243687
http://dx.doi.org/10.1002/ana.26343
work_keys_str_mv AT brilllivnat severeacuterespiratorysyndromecoronavirus2thirdvaccineimmuneresponseinmultiplesclerosispatientstreatedwithocrelizumab
AT raposocatarina severeacuterespiratorysyndromecoronavirus2thirdvaccineimmuneresponseinmultiplesclerosispatientstreatedwithocrelizumab
AT rechtmanariel severeacuterespiratorysyndromecoronavirus2thirdvaccineimmuneresponseinmultiplesclerosispatientstreatedwithocrelizumab
AT zveikomri severeacuterespiratorysyndromecoronavirus2thirdvaccineimmuneresponseinmultiplesclerosispatientstreatedwithocrelizumab
AT levinnetta severeacuterespiratorysyndromecoronavirus2thirdvaccineimmuneresponseinmultiplesclerosispatientstreatedwithocrelizumab
AT oikninedjianesther severeacuterespiratorysyndromecoronavirus2thirdvaccineimmuneresponseinmultiplesclerosispatientstreatedwithocrelizumab
AT wolfdanag severeacuterespiratorysyndromecoronavirus2thirdvaccineimmuneresponseinmultiplesclerosispatientstreatedwithocrelizumab
AT vaknindembinskyadi severeacuterespiratorysyndromecoronavirus2thirdvaccineimmuneresponseinmultiplesclerosispatientstreatedwithocrelizumab

Ejemplares similares